This trial will test a new drug for kidney cancer. The first part will find the best dose of the drug, and the second part will see if it works.
- Clear Cell Renal Cell Carcinoma
- Kidney Cancer
- Renal Cell Carcinoma Recurrent
- Kidney Tumors
- Refractory Renal Cell Carcinoma
3 Primary · 10 Secondary · Reporting Duration: Approximately 2 years
2 Treatment Groups
Phase 2 dose expansion
1 of 2
Phase 1 dose escalation
1 of 2
98 Total Participants · 2 Treatment Groups
Primary Treatment: Oral NKT2152 · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any slots left in this experiment accessible to participants?
"Correct. According to data hosted on clinicaltrials.gov, this medical study that was initially advertised on October 26th 2021 is currently searching for participants. A total of 98 patients are sought from 7 different centres." - Anonymous Online Contributor
What is the current population enrolled in this clinical research?
"Affirmative, the trial is actively seeking enrollees. The posting was initially put up on October 26th 2021 and most recently updated on October 17th 2022. This initiative requires 98 participants from 7 different clinical sites to reach completion." - Anonymous Online Contributor
Are there any Canadian locations conducting this medical experiment?
"This clinical trial is being conducted in multiple locations, such as the National Cancer Institute in Bethesda and MD Anderson Cancer Center in Houston. Additionally, sites at Dana Farber Cancer Institute (Boston) and 7 other centers are included." - Anonymous Online Contributor
What outcome is this trial aiming to demonstrate?
"According to the study sponsor, NiKang Therapeutics Inc., this clinical trial will measure a primary outcome of Objective Response Rate (ORR) over 21 days during the Dose Expansion Phase (Phase 2). The investigation will also gauge secondary outcomes such as Overall Survival (OS), which is measured from commencement of treatment until death due to any cause, Disease Control Rate (DCR), and Time To Maximum Observed Plasma Concentration Of NKT2152(Tmax)." - Anonymous Online Contributor